Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial

Objective: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolera...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Child Adolesc Psychopharmacol
Главные авторы: Aman, Michael, Rettiganti, Mallikarjuna, Nagaraja, Haikady N., Hollway, Jill A., McCracken, James, McDougle, Christopher J., Tierney, Elaine, Scahill, Lawrence, Arnold, L. Eugene, Hellings, Jessica, Posey, David J., Swiezy, Naomi B., Ghuman, Jaswinder, Grados, Marco, Shah, Bhavik, Vitiello, Benedetto
Формат: Artigo
Язык:Inglês
Опубликовано: Mary Ann Liebert, Inc. 2015
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4545698/
https://ncbi.nlm.nih.gov/pubmed/26262903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2015.0005
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы